Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C413566-5mg | 5mg | In stock | $98.90 | |
C413566-25mg | 25mg | In stock | $445.90 | |
C413566-100mg | 100mg | In stock | $741.90 |
Adenosine Receptor Antagonists
Synonyms | NSC801812 | NSC-801812 | EX-A1716 | UNII-8KFO2187CP | HY-101978 | s6646 | ciforadenant | Ciforadenant [USAN:INN] | A-chloroethyl) phosphate | V81444;Triazolo-pyramidine derivative | CPI 444 | (S)-7-(5-methylfuran-2-yl)-3-((6-(((tetrahydrofuran-3-yl)oxy)me |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Ciforadenant\xa0(CPI-444, V81444) is a potent and selective Adenosine A2A receptor antagonist. It binds to A2A receptors with a Ki of 3.54 nmol/L and demonstrates a greater than 50-fold selectivity for the A2A receptor over other adenosine receptor subtyp |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Adenosine A2a receptor antagonist |
Product Description | Information Ciforadenant (CPI-444) Ciforadenant (CPI-444, V81444) is a potent and selective Adenosine A2A receptor antagonist. It binds to A2A receptors with a Ki of 3.54 nmol/L and demonstrates a greater than 50-fold selectivity for the A2A receptor over other adenosine receptor subtypes. Targets A2AR 3.54 nM(Ki) In vitro CPI-444 restores T-cell activation in vitro. In vivo CPI-444 treatment resulted in a similar inhibition of tumor growth in the B16F10 melanoma (100 mg/kg) and RENCA renal cell cancer syngeneic models (10 mg/kg). It enhances T-cell activation in both the periphery and tumor microenvironment. |
ALogP | 1.769 |
---|---|
HBD Count | 1 |
Rotatable Bond | 6 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|---|---|---|---|---|---|---|
Adenosine A1 receptor partial agonist | PARTIAL AGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Adenosine A1 receptor agonist | AGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Adenosine A1 receptor antagonist | ANTAGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Adenosine A1 receptor agonist | AGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Adenosine A1 receptor antagonist | ANTAGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | PubMed: [1] | |
Adenosine A1 receptor agonist | AGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Adenosine A1 receptor agonist | AGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | Other: [1] | |
Adenosine A1 receptor antagonist | ANTAGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | Other: [1] | |
Adenosine A1 receptor agonist | AGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens | ||
Adenosine A1 receptor agonist | AGONIST | ALA226 | Adenosine A1 receptor | SINGLE PROTEIN | Homo sapiens |
Pubchem Sid | 504770362 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504770362 |
IUPAC Name | 7-(5-methylfuran-2-yl)-3-[[6-[[(3S)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine |
INCHI | InChI=1S/C20H21N7O3/c1-12-5-6-16(30-12)17-18-19(24-20(21)23-17)27(26-25-18)9-13-3-2-4-14(22-13)10-29-15-7-8-28-11-15/h2-6,15H,7-11H2,1H3,(H2,21,23,24)/t15-/m0/s1 |
InChi Key | KURQKNMKCGYWRJ-HNNXBMFYSA-N |
Canonical SMILES | CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)COC5CCOC5 |
Isomeric SMILES | CC1=CC=C(O1)C2=C3C(=NC(=N2)N)N(N=N3)CC4=NC(=CC=C4)CO[C@H]5CCOC5 |
PubChem CID | 44537963 |
Molecular Weight | 407.43 |
Solubility | Solubility (25°C) In vitro DMSO: 81 mg/mL (198.8 mM); Water: Insoluble; Ethanol: Insoluble;DMSO (Slightly), Methanol (Slightly) |
---|---|
DMSO(mg / mL) Max Solubility | 81 |
DMSO(mM) Max Solubility | 198.807157057654 |
Water(mg / mL) Max Solubility | <1 |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. |
1. Leone RD, Sun IM, Oh MH, Sun IH, Wen J, Englert J, Powell JD. (2018) Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.. Cancer Immunol Immunother, 67 (8): (1271-1284). [PMID:29923026] [10.1021/op500134e] |
2. Willingham SB, Ho PY, Hotson A, Hill C, Piccione EC, Hsieh J, Liu L, Buggy JJ, McCaffery I, Miller RA. (2018) A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.. Cancer Immunol Res, 6 (10): (1136-1149). [PMID:30131376] [10.1021/op500134e] |